Elizabeth C. Cushman, Executive Vice President at Abbott Laboratories (ABT), reported a tax-related disposition of 560 common shares for tax withholdi...
Amidst political tensions and market volatility, this article highlights three US blue-chip defensive stocks: Abbott Laboratories (ABT), Constellation...
Bullish
Abbott Laboratories (NYSE: ABT) is highlighted as a strong dividend growth stock, particularly valuable in volatile markets. As a Dividend King with 5...
Bullish
Abbott Laboratories (ABT) is expanding its market presence by launching its Instinct continuous glucose monitoring (CGM) sensor across Europe, integra...
Neutral
Abbott Laboratories (ABT) stock increased by 3.12% due to strategic initiatives, strong analyst support, and its status as a dividend aristocrat. Key ...
Neutral
Abbott Laboratories (ABT) shares have dropped significantly, but the company is considered a strong buy due to its FreeStyle Libre continuous glucose ...
Abbott (NYSE:ABT) announced it will release its second-quarter 2026 earnings on Thursday, July 16, 2026, before the market opens. Following the earnin...
Bullish
Abbott Laboratories (NYSE: ABT) is highlighted as an "unstoppable dividend aristocrat" with a strong business model, suitable for long-term ownership....
Neutral
MiniMed has commercially launched its MiniMed 780G automated insulin delivery system, integrated with Abbott's Instinct sensor, and the MiniMed Go sys...
Bullish
Abbott Laboratories (ABT) has launched two new diabetes management systems, MiniMed 780G with Instinct sensor and MiniMed Go with Instinct Go sensor, ...
Bearish
A Missouri appeals court has declined to send Abbott Laboratories' appeal of a $495 million verdict to the Missouri Supreme Court, leaving the 2024 ve...
Bullish
Piper Sandler has reiterated an Overweight rating and a $115.00 price target for Abbott Laboratories (NYSE:ABT), anticipating accelerating growth in f...
Neutral
Auto Owners Insurance Co lifted its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 12,429.0% in the fourth quarter, according t...
This article examines three US dividend growth stocks—Abbott Laboratories (ABT), Stryker (SYK), and Masco (MAS)—in the context of higher short-term bo...
John G. Stratton, a director at Abbott Laboratories (NYSE: ABT), recently purchased 2,000 common shares of the company on the open market. The transac...
Bullish
Abbott recently announced its 410th consecutive quarterly dividend of US$0.63 per share and launched its CE-marked dual glucose-ketone Libre Duo senso...
Neutral
Atlas Capital Advisors Inc. purchased a new position in Abbott Laboratories (NYSE:ABT – Free Report) in the 4th quarter, according to the company in i...
Bullish
BofA analyst Travis Steed lowered the price objective for Abbott Laboratories (ABT) to $102 from $120, maintaining a “Buy” rating, due to conservative...
Neutral
Abbott Laboratories (ABT) is highlighted as one of the top longevity stocks, with recent announcements focusing on its advancements in diabetes care, ...
This article reports that Abbott Laboratories has declared a quarterly dividend of $0.63 per share. This financial action indicates the company's comm...